The content on this site is intended for healthcare professionals only
Dr Gil Morgan from OncoAlert gives his oncology highlights from social media for the week of August 11th - 17th, 2023.
He begins by highlighting the FDA approval of niraparib and abiraterone acetate with prednisone for treating of BRCA mutated castration-resistant prostate cancer.
Dr Morgan also covers results from the TITAN trial which used apalutamide versus placebo for patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy.
In addition, he comments on the PERNETTA trial, which involved the use of pertuzumab and trastuzumab followed by emtansine for ERBB2-positive metastatic breast cancer.
Follow Dr Morgan on twitter: @OncoAlert
Follow ecancer on twitter: @ecancer
KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer
Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall survival rates in patients with resectable CSCC
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
The Southeast Asian Breast Cancer Symposium; background, aims and successes
OncoAlert Round Up for August 4th - 10th, 2023
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
The use of IORT at Universitätsmedizin Mannheim hospital
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours
Advancing breast cancer diagnosis in the developing world
